Amneal Pharmaceuticals (AMRX) Revenue & Revenue Breakdown
Amneal Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$2.39B
Latest Revenue (Q)
$701.78M
Main Segment (Y)
Generics Segment
Main Geography (Y)
Generics Segment
Amneal Pharmaceuticals Revenue by Period
Amneal Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $2.39B | 8.20% |
| 2022-12-31 | $2.21B | 5.67% |
| 2021-12-31 | $2.09B | 5.08% |
| 2020-12-31 | $1.99B | 22.51% |
| 2019-12-31 | $1.63B | -2.20% |
| 2018-12-31 | $1.66B | 60.88% |
| 2017-12-31 | $1.03B | 1.52% |
| 2016-12-31 | $1.02B | - |
Amneal Pharmaceuticals generated $2.39B in revenue during NA 2023, up 8.20% compared to the previous quarter, and up 143.93% compared to the same period a year ago.
Amneal Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $701.78M | 6.46% |
| 2024-03-31 | $659.19M | 6.84% |
| 2023-12-31 | $616.98M | -0.49% |
| 2023-09-30 | $620.04M | 3.50% |
| 2023-06-30 | $599.05M | 7.44% |
| 2023-03-31 | $557.54M | -8.56% |
| 2022-12-31 | $609.76M | 11.77% |
| 2022-09-30 | $545.56M | -2.47% |
| 2022-06-30 | $559.36M | 12.40% |
| 2022-03-31 | $497.63M | -7.31% |
| 2021-12-31 | $536.90M | 1.57% |
| 2021-09-30 | $528.59M | -1.21% |
| 2021-06-30 | $535.08M | 8.51% |
| 2021-03-31 | $493.11M | -3.32% |
| 2020-12-31 | $510.03M | -1.78% |
| 2020-09-30 | $519.29M | 11.76% |
| 2020-06-30 | $464.66M | -6.79% |
| 2020-03-31 | $498.53M | 25.47% |
| 2019-12-31 | $397.33M | 5.03% |
| 2019-09-30 | $378.28M | -6.51% |
| 2019-06-30 | $404.64M | -9.30% |
| 2019-03-31 | $446.12M | -10.33% |
| 2018-12-31 | $497.53M | 4.42% |
| 2018-09-30 | $476.49M | 15.15% |
| 2018-06-30 | $413.79M | 50.36% |
| 2018-03-31 | $275.19M | -6.20% |
| 2017-12-31 | $293.37M | 15.17% |
| 2017-09-30 | $254.73M | -1.98% |
| 2017-06-30 | $259.87M | 15.15% |
| 2017-03-31 | $225.68M | -24.41% |
| 2016-12-31 | $298.58M | - |
Amneal Pharmaceuticals generated $701.78M in revenue during Q2 2024, up 6.46% compared to the previous quarter, and up 125.87% compared to the same period a year ago.
Amneal Pharmaceuticals Revenue Breakdown
Amneal Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Specialty Segment | $390.46M | $317.53M | - | - | - |
| Generics Segment | $1.47B | $1.43B | $1.37B | $1.34B | $1.29B |
| Amneal Specialty Pharma Segment | - | $374.12M | $378.32M | $355.57M | - |
| Av K A R E Segment | - | $406.11M | - | - | - |
| Av Kare | - | - | $349.01M | $293.75M | - |
Amneal Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Generics Segment (79.03%), and Specialty Segment (20.97%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal Specialty Pharma Segment | $105.23M | $96.99M | $91.68M | $102.55M | $89.48M | $97.00M | $85.09M | $101.01M | $92.75M | $95.93M | $85.47M | $87.87M | $94.26M | $97.05M | - | - | - | - | - | - |
| Generics Segment | $391.29M | $753.89M | $373.70M | $343.81M | $399.17M | $350.27M | $364.89M | $317.75M | $346.27M | $347.13M | $360.44M | $312.51M | $342.14M | $341.92M | $306.56M | $985.00K | $300.28M | - | - | - |
| Av K A R E Segment | - | - | $128.35M | $122.06M | $108.04M | $105.81M | $97.46M | $94.80M | $88.72M | $86.00M | $84.67M | $89.51M | $63.85M | $57.97M | - | - | - | - | - | - |
| Specialty Segment | - | - | - | - | - | - | - | - | - | - | $88.64M | $87.98M | - | - | - | - | - | - | - | - |
| Diclofenac Sodium Gel | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $19.26M | $25.01M | $23.47M |
| Epinephrine Auto Injector Family Generic Adrenaclick | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $22.69M | - | - |
| Levothyroxine Sodium | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $39.77M | $46.46M | $48.99M |
| Oxymorphone | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $17.14M | - | - |
| Rytary Family | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $33.71M | $33.00M | $28.83M |
| Epinephrine Auto-Injector Family (Generic Adrenaclick) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $15.96M | $15.20M |
| Yuvafem-Estradiol | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $14.02M | $18.74M |
Amneal Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Generics Segment (78.81%), and Amneal Specialty Pharma Segment (21.19%).
Amneal Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Generics Segment | $1.47B | $41.09M | $35.97M | $37.39M | $1.29B |
| Specialty Segment | $390.46M | $374.12M | $378.32M | $355.57M | $317.53M |
Amneal Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 23: Generics Segment (79.03%), and Specialty Segment (20.97%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specialty Segment | $105.23M | $201.78M | $96.99M | $91.68M | $102.55M | $89.48M | $97.00M | $85.09M | $101.01M | $92.75M | $88.64M | $95.93M | $85.47M | $87.87M | $94.26M | $87.98M | - | - | - | - |
| Generics Segment | $391.29M | $1.45B | $11.14M | $12.81M | $14.58M | $8.72M | $12.12M | $5.67M | $9.09M | $8.23M | $10.46M | $8.18M | $9.19M | $10.88M | $7.24M | $985.00K | $300.28M | $291.02M | $335.06M | $382.48M |
Amneal Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Mar 24: Generics Segment (78.81%), and Specialty Segment (21.19%).
Amneal Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMRX | Amneal Pharmaceuticals | $2.39B | $701.78M |
| NBIX | Neurocrine Biosciences | $1.89B | $590.20M |
| ALKS | Alkermes | $1.66B | $399.13M |
| PAHC | Phibro Animal Health | $977.89M | $263.22M |
| AMPH | Amphastar Pharmaceuticals | $593.24M | $182.39M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| ITCI | Intra-Cellular Therapies | $462.18M | $144.87M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $94.40M |
| PROC | Procaps Group | $409.92M | $118.41M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| DVAX | Dynavax | $232.28M | $73.80M |
| EOLS | Evolus | $199.72M | $66.22M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| ASRT | Assertio | $152.07M | $31.13M |
| LFCR | Lifecore Biomedical | $128.26M | $35.70M |
| AGRX | Agile Therapeutics | $19.59M | $5.58M |
| SSIC | Silver Spike Investment | $11.72M | $2.76B |
| ACRX | Talphera | $651.00K | $117.00K |
AMRX Revenue FAQ
What is Amneal Pharmaceuticals’s yearly revenue?
Amneal Pharmaceuticals's yearly revenue for 2023 was $2.39B, representing an increase of 8.20% compared to 2022. The company's yearly revenue for 2022 was $2.21B, representing an increase of 5.67% compared to 2021. AMRX's yearly revenue for 2021 was $2.09B, representing an increase of 5.08% compared to 2020.
What is Amneal Pharmaceuticals’s quarterly revenue?
Amneal Pharmaceuticals's quarterly revenue for Q2 2024 was $701.78M, a 6.46% increase from the previous quarter (Q1 2024), and a 17.15% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $659.19M, a 6.84% increase from the previous quarter (Q4 2023), and a 18.23% increase year-over-year (Q1 2023). AMRX's quarterly revenue for Q4 2023 was $616.98M, a -0.49% decrease from the previous quarter (Q3 2023), and a 1.18% increase year-over-year (Q4 2022).
What is Amneal Pharmaceuticals’s revenue growth rate?
Amneal Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 14.33%, and for the last 5 years (2019-2023) was 47.17%.
What are Amneal Pharmaceuticals’s revenue streams?
Amneal Pharmaceuticals's revenue streams in c 23 are Specialty Segment, and Generics Segment. Specialty Segment generated $390.46M in revenue, accounting 20.97% of the company's total revenue, up 22.97% year-over-year. Generics Segment generated $1.47B in revenue, accounting 79.03% of the company's total revenue, up 2.75% year-over-year.
What is Amneal Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Amneal Pharmaceuticals was Generics Segment. This segment made a revenue of $1.47B, representing 79.03% of the company's total revenue.